CD8A and neoplasm: However, no significant tumor regression by WNK463 treatment was found in CD8+ T-cell-depleted mice (Supplementary Fig. 4c and Fig. 5f, right), although PD-L1 expression consistently decreased in this context (Supplementary Fig. 4d), indicating the crucial roles of CD8+ T cells in WNK463-mediated antitumor activity.